Antithrombotic Treatment for Peripheral Arterial Occlusive Disease
CONCLUSION: Antiplatelet therapy should only be intensified for a limited time, or if the risk of ischemia is high. Before and during intensified antiplatelet therapy, the risk of bleeding should be assessed and weighed against the risk of ischemia. No validated score is available to estimate the risk of hemorrhagic complications in patients with PAOD. New antithrombotic therapies should not be used indiscriminately, but should rather be reserved for selected groups of patients.PMID:33734081 | DOI:10.3238/arztebl.m2021.0157
Source: Deutsches Arzteblatt International - Category: General Medicine Authors: David Hardung Andrea Behne Mehmet Boral Carsten Giesche Ralf Langhoff Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Endocrinology | General Medicine | Germany Health | Heart | Hemorrhagic Stroke | Nicotine | Stroke